Trevi Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 663.28K shares, a 12936.18% increase year-over-year.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 104.99K shares, a 63.83% decline year-over-year.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 78.71K shares, a 319.67% increase year-over-year.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 477.49K shares, a 319.82% increase year-over-year.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 851.57K shares, a 225.01% increase from fiscal 2024.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 262.01K shares, a 79.36% increase from fiscal 2023.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 146.08K shares, a 186.41% increase from fiscal 2022.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 51.01K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 663.28K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 1.32M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 104.99K shares 10-Q · filed 2026-05-05 | 666.27K shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 78.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 851.57K shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 477.49K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 791.61K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 5.09K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 427.86K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 290.28K shares 10-Q · filed 2025-05-08 | 549.66K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 18.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 262.01K shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 113.74K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 245.55K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 126.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 138.69K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 2.63K shares 10-Q · filed 2024-05-07 | 26.73K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 2.29K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | 146.08K shares 10-K · filed 2024-03-20 |
| 2023-09-30 | 6.88K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 143.79K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 14.94K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | |
| 2023-03-31 | 121.98K shares 10-Q · filed 2023-05-11 | |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 51.01K shares 10-K · filed 2023-03-16 |
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 18.34K shares 10-K · filed 2021-03-25 |
| 2020-09-30 | 3.16K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | 14.74K shares 10-K · filed 2020-03-16 |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | |
| 2019-06-30 | 6.84K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | |
| 2019-03-31 | 7.89K shares 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |